Algavac® M (Algavac® M)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceNiclosamideNiclosamide
Similar drugsTo uncover
  • Algavac® M
    suspension w / m 
    Vector-BiAlgam, CJSC    
    • Dosage form: & nbspsuspension for intramuscular injection
    Composition:

    1 ml of the preparation contains at least 50 ELISA units of inactivated antigen of the hepatitis A virus, 0.5 mg of aluminum hydroxide, not more than 0.15 mg of formaldehyde and 0.01 M phosphate-buffered saline (up to 1 ml). The vaccine does not contain preservatives and antibiotics.

    Description:The vaccine is a virion of hepatitis A (strain LBA-86) grown on a culture of inoculated cells 4647, purified, concentrated, inactivated and adsorbed on an aluminum hydroxide gel. A slightly opalescent suspension settling upon settling is divided into two layers: the upper one is a clear, colorless liquid; the bottom is a white precipitate that breaks easily when shaken, without the formation of flakes and the presence of foreign inclusions
    Pharmacotherapeutic group:MIBP vaccine
    ATX: & nbsp

    P.02.D.A.01   Niclosamide

    Pharmacodynamics:

    The full course of vaccination ensures the development of a long-term specific immunity in 90-95% of the vaccinated.

    Indications:

    Active prophylaxis of viral hepatitis A in children aged 3 years, adolescents and adults.

    Vaccination is subject to persons who are or will be be at risk of contracting viral hepatitis A:

    1. Persons living in areas with a high incidence of hepatitis A;
    2. Persons traveling to regions with a high incidence of hepatitis A (military personnel, travelers, etc.);
    3. Persons contact in the hearths;
    4. Persons at occupational risk of infection: medical personnel and nursing staff (especially in infectious, gastroenterological and pediatric departments); personnel of preschool institutions; employees of sewerage and water supply services; personnel of the food industry and public catering establishments;
    5. Individuals at special risk groups (patients with chronic liver disease or an increased risk of liver disease, patients with hemophilia, patients with multiple blood transfusions, drug addicts, homosexuals, people with promiscuity).

    Vaccinations can also be carried out by other groups of the population.

    Contraindications:

    1. Acute infectious and non-infectious diseases, exacerbations of chronic diseases. The vaccine is given not earlier than 1 month after recovery (remission).

    2.A strong reaction (temperature above 40 ° C, hyperemia, edema at the injection site with a diameter of more than 8 cm) with the previous administration of the drug.

    3. Immunodeficiency states, malignant blood diseases and neoplasms.

    4. Pregnancy.

    5. Hypersensitivity to any component of the vaccine.

    In order to identify contraindications, the doctor (paramedic) on the day of vaccination conducts an examination and a survey of the vaccinated with mandatory thermometry. If necessary, conduct appropriate laboratory examination.

    Dosing and Administration:

    The vaccine is injected intramuscularly into the deltoid muscle (shoulder muscle).

    One inoculum dose is: for children and adolescents - 0.5 ml, for adults - 1.0 ml. The vaccination course, providing long-term protection against hepatitis A, consists of two vaccinations conducted at intervals 6-12 months. Single injection of the vaccine provides protection from infection for up to 12 months.

    Intravenous injection of the vaccine is not allowed!

    Opening of ampoules and the vaccination procedure are carried out with strict adherence to aseptic and antiseptic rules. Before typing in a syringe, the vaccine is thoroughly mixed by shaking the ampoule.When using an ampoule containing several doses, each dose should be administered using a separate sterile syringe with a sterile needle. The vaccine from the opened multi-dose ampoule should be used within 30 minutes.

    The preparation is not suitable for use in ampoules with broken integrity, marking, and also with changing physical properties (color, transparency, etc.). The vaccinations are recorded in the established registration forms with the indication of the date, dose, manufacturer, serial number, response to vaccination.

    Side effects:In rare cases, vaccinated people may experience malaise, headache, short-term low-grade fever. In rare cases there is a rapid passing insignificant soreness or twitching of the muscles at the site of administration of the vaccine, as well as a slight hyperemia of the skin or mild edema that pass through 1-2 days.

    Considering the theoretical possibility of developing allergic reactions of immediate type in particularly sensitive individuals, it is necessary to provide medical supervision for vaccinated persons within 30 minutes. Vaccination sites should be provided with anti-shock therapy.

    Interaction:

    It is allowed to apply Algavac® M together with other inactivated vaccines of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemiological indications (except rabies vaccine), provided vaccines are administered to different parts of the body.

    The vaccine should not be mixed in the same syringe with other vaccines.

    Form release / dosage:Suspension for intramuscular injection.
    Packaging:

    In ampoules of 0.5 ml (1 infant dose); 1.0 ml (1 adult dose or 2 children's doses); 2.0 ml (2 adults or 4 children's doses).

    5 or 10 ampoules are placed in boxes of cardboard with instructions for use and an ampoule knife.

    5 ampoules are placed in an open contour mesh package (blister) made of a polyvinyl chloride film. 1 or 2 contour mesh packages are placed in carton boxes with instructions for use and an ampoule knife.

    When using ampoules with notches or rings, the ampoule knife is not inserted.

    Storage conditions:

    The vaccine is stored and transported in accordance with SP 3.3.2.1248-03 at a temperature of 2 ° C to 8 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    Shelf life 2 years.

    The drug with expired shelf life is not subject to application.
    Terms of leave from pharmacies:For hospitals
    Registration number:P N000461 / 01
    Date of registration:29.05.2007 / 10.02.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:Vector-BiAlgam, CJSCVector-BiAlgam, CJSC
    Manufacturer: & nbsp
    Information update date: & nbsp16.07.2017
    Illustrated instructions
      Instructions
      Up